Vacuolar ATPase regulates zymogen activation in pancreatic acini.
Supramaximal concentrations of cholecystokinin or its analogue caerulein have been shown to stimulate the proteolytic activation of zymogens within the pancreatic acinar cell and initiate acute pancreatitis. Previous studies suggest that a low pH compartment might be required for activation. To test this hypothesis, the effects of agents that modulate intracellular pH on caerulein-induced trypsin and chymotrypsin activation were studied. Pretreatment of pancreatic acini with the proto-ionophore monensin (10 microM) and the weak base chloroquine (40 microM) inhibited activation. Pre-incubation with the vacuolar ATPase (V-ATPase) inhibitors bafilomycin A(1) and concanamycin A also decreased activation in a concentration-dependent manner with 50% inhibition at approximately 50 and 25 nM, respectively. Caerulein stimulation caused a time- and concentration-dependent translocation of soluble V-ATPase V(1) subunits to a membrane fraction, a marker of V-ATPase activation. Carbachol also stimulated translocation at supramaximal concentrations. Elevation of cytosolic Ca(2+) by thapsigargin was sufficient to induce translocation. Thus, stimulation of V-ATPase activity appears to be required for agonist-induced zymogen activation in the pancreatic acinar cell.
Waterford
Stephen D
SD
Department of Internal Medicine, Section of Digestive Diseases, Veteran Administration Connecticut Healthcare, West Haven, CT 06516, USA.
Kolodecik
Thomas R
TR
Thrower
Edwin C
EC
Gorelick
Fred S
FS
D000681:Amylases / Q000378:metabolism; D000818:Animals; D002118:Calcium / Q000378:metabolism; D002217:Carbachol / Q000494:pharmacology; D002462:Cell Membrane / Q000187:drug effects / Q000378:metabolism; D002478:Cells, Cultured; D002108:Ceruletide / Q000494:pharmacology; D002738:Chloroquine / Q000494:pharmacology; D002918:Chymotrypsin / Q000378:metabolism; D004789:Enzyme Activation / Q000187:drug effects; D004792:Enzyme Precursors / Q000378:metabolism*; D006863:Hydrogen-Ion Concentration; D018942:Macrolides / Q000494:pharmacology; D008297:Male; D008985:Monensin / Q000494:pharmacology; D010179:Pancreas / Q000166:cytology* / Q000187:drug effects / Q000201:enzymology / Q000378:metabolism*; D021122:Protein Subunits / Q000819:agonists / Q000378:metabolism; D021381:Protein Transport / Q000187:drug effects; D051381:Rats; D017207:Rats, Sprague-Dawley; D012995:Solubility; D019284:Thapsigargin / Q000494:pharmacology; D014357:Trypsin / Q000378:metabolism; D025262:Vacuolar Proton-Translocating ATPases / Q000037:antagonists & inhibitors / Q000378:metabolism*
D004792:Enzyme Precursors; D018942:Macrolides; D021122:Protein Subunits; C057620:bafilomycin A; D019284:Thapsigargin; C036978:concanamycin A; D002738:Chloroquine; D002108:Ceruletide; D002217:Carbachol; D008985:Monensin; D000681:Amylases; D002918:Chymotrypsin; D014357:Trypsin; D025262:Vacuolar Proton-Translocating ATPases; D002118:Calcium